sofosbuvir/velpatasvir / Generic mfg. - LARVOL DELTA

MINMON-J: Implementing Low-Barrier HCV Treatment in a Jail Setting (clinicaltrials.gov) - P4 | N=40 | Not yet recruiting | Sponsor: Lifespan

New P4 trial • Hepatitis C • Hepatology • Infectious Disease • Inflammation

TeleHCV: A single-visit protocol and minimal passive remote monitoring are sufficient to achieve high SVR with a sofosbuvir-velpatasvir regimen. (PubMed, Clinics (Sao Paulo)) - P=N/A | "This simplified strategy achieved a high SVR rate in a population with restricted access to specialized care. Telehealth tools and minimal monitoring are promising components for policies aimed at HCV elimination."

Journal • Hepatitis C • Hepatology • Infectious Disease • Inflammation

Changes in liver stiffness and steatosis in children after successful treatment with sofosbuvir/velpatasvir: Results of the PANDAA-PED study. (PubMed, Clin Exp Hepatol) - "However, its regression may occur to some extent after successful treatment with SOF/VEL. A transient increase in hepatic steatosis was observed after eradication of HCV, which requires further investigation."

Journal • Fibrosis • Hepatitis C • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis

Cost-Effectiveness of Screening and Treating Chronic Hepatitis C Virus Infection in Zimbabwe. (PubMed, Int J Environ Res Public Health) - "Screening for HCV among high-risk populations followed by treatment using sofosbuvir/velpatasvir is cost effective under the assumptions made in this study."

HEOR • Journal • Hepatitis C • Hepatology • Infectious Disease • Inflammation

A Case of Primary Hepatocellular carcinoma with a 12cm Contralateral Indeterminate Left Adrenal mass. (ENDO 2025) - "Case Description:A 71-year-old male with a medical history of compensated Hepatitis C cirrhosis on Epclusa/Ribavirin was undergoing computed tomography (CT) of chest due to a smoking history and known pulmonary nodules. Adrenal biopsy can be considered in select cases of indeterminate adrenal masses with known history of extra-adrenal malignancy, but pheochromocytoma must be ruled out prior.*. .*"

Clinical • Adrenal Cortex Carcinoma • Endocrine Cancer • Fibrosis • Genito-urinary Cancer • Hepatitis C • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Oncology • Solid Tumor

Long-term prognosis and changes in liver function after direct-acting antiviral treatment in decompensated cirrhotic patients with hepatitis C virus (EASL 2025) - "All patients were treated with 12 weeks of sofosbuvir and velpatasvir... In decompensated cirrhotic patients with HCV treated with DAA, liver function improved up to 24 weeks after the EOT, but may deteriorate at 5 years after the EOT. The 5-year LT-free survival rate was 69.0%, and virologic response and Child-Pugh class at 12 weeks after the EOT were associated with LT-free survival."

Clinical • Fibrosis • Hepatitis C • Hepatocellular Cancer • Hepatology • Infectious Disease • Inflammation • Liver Cirrhosis • Oncology • Solid Tumor

Treatment of genotype 3 chronic hepatitis C infection: age reduces the efficacy of treatment with sofosbuvir and daclatasvir but the reduction is less marked with sofosbuvir and velpatasvir (EASL 2025) - "Efficacy with sofosbuvir/daclatasvir reduces by a modest amount with increasing age in Pakistan. This reduction is less marked but also seen in people with genotype 3 treated with sofosbuvir/velpatasvir in England. This likely reflects the higher rate of cirrhosis and co-morbidity in the elderly."

Clinical • Fibrosis • Hepatitis C • Hepatology • Infectious Disease • Inflammation

A decade of hepatitis C virus management: insights from a large population-based cohort on treatment patterns, adherence, and outcomes (EASL 2025) - "SVR rates were higher with newer pangenotypic regimens such as Epclusa (96.4%) and Maviret (96.2%) compared to older medications but markedly lower in DAA-experienced patients (85.0%) and those with moderate-to-low adherence (56.8%). This comprehensive decade-long analysis underscores critical insights into the management and outcomes of HCV in a large, population-based cohort, revealing that while high SVR rates are achievable, adherence remains a pivotal determinant of success. Our findings highlight specific subpopulations at risk for poor adherence and incomplete follow- up, emphasizing the need for targeted interventions to address these barriers in the pursuit of HCV eradication."

Adherence • Clinical • Addiction (Opioid and Alcohol) • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Depression • Diabetes • Fibrosis • Hepatitis C • Hepatocellular Cancer • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Major Depressive Disorder • Metabolic Disorders • Mood Disorders • Obesity • Oncology • Psychiatry • Solid Tumor

Healthcare resource use (HCRU) and cost impact of potential drug-drug interactions (DDIs) among HCV patients receiving Direct-Acting Antivirals (DAAs) concomitantly with antipsychotic drugs in the US (EASL 2025) - "We explored the use of antipsychotic drugs in a US claims database concomitantly with the use of any of the two pangenotypic DAAs, sofosbuvir/velpatasvir (SOF/VEL) or glecaprevir/pibrentasvir (GLE/PIB), evaluating the risk of associated DDIs, quality of the prescriptions based on the DDI risk, and the related healthcare resource use and costs. Despite the extended recognition of the use of the Liverpool HEP DDI tracker by all HCV treatment guidelines, this analysis of the DAAs based on the DDI risk demonstrates importance of safety monitoring of patients and the need for individualized medicine to ensure an appropriate DAA is used in patients with polypharmacy. Additionally, compared to GLE/PIB, SOF/VEL presents lower DDI risk and lower outpatient costs in the HCV patients receiving DAA treatment concomitantly with antipsychotic drugs."

Clinical • CNS Disorders • Hepatitis C

The SVR10K Hepatitis C study: final results show 98.9% SVR in 7,000 patients treated with SOF/VEL in Asia, Latin America, Middle East, Nordic and Southern Europe (EASL 2025) - "Background and Aims: A previously published real-world data analysis demonstrated high effectiveness of sofosbuvir/velpatasvir (SOF/VEL) in > 6,000 HCV patients from 12 clinical cohorts across Australia, Canada, Europe & USA... Results on treatment effectiveness in diverse geographical regions did not differ from real world studies of patients in Western countries, reinforcing the effectiveness of pangenotypic / panfibrotic / pangeographic DAA therapy such as SOF/VEL and supporting the global applicability of HCV treatment guidelines."

Clinical • CNS Disorders • Fibrosis • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Mental Retardation • Psychiatry

Health economic outcomes of a minimal monitoring approach to providing HCV therapy. (PubMed, Hepatol Commun) - "MINMON is a cost-saving strategy for HCV treatment, particularly in low- and middle-income country settings."

HEOR • Journal • Hepatitis C • Hepatology • Infectious Disease • Inflammation

Prescription patterns of comedications associated with drug-drug interactions risk in HCV-infected patients undergoing direct-acting antiviral treatment: an analysis of an administrative claims database in Japan. (PubMed, J Pharm Health Care Sci) - "A considerable proportion of patients were prescribed medications with DDI risk during DAA treatment. A small but notable proportion of patients were on "Contraindication (Red)" medications. Consideration of the potential DDI risks associated with comedications by healthcare professionals is advised, referring not only to package inserts but also tools such as Liverpool HEP checker to guide safe prescribing when initiating DAA therapy for HCV patients."

Journal • Hepatitis C • Hepatology • Infectious Disease • Inflammation

Retreatment of Hepatitis C Virus Among People Who Inject Drugs. (PubMed, Clin Infect Dis) - "After reinfection or not achieving SVR with the first DAA regimen, retreated PWID achieved higher SVR rates than with initial DAA treatment. To attain HCV elimination and benefit individual and public health, assisting PWID with accessing prompt retreatment is crucial."

Journal • Hepatitis C • Hepatology • Infectious Disease • Inflammation

Treatment Failure of Sofosbuvir/Velpatasvir for Donor-Derived Hepatitis C Genotype 3 (ISHLT 2025) - "He received induction immunosuppression with basiliximab, followed by tacrolimus, mycophenolate, and steroid taper. On PTD 295, he started a 24-week course of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX), with undetectable viral load as of PTD 407.Summary Organs from HCV-infected donors remain a viable option, but providers must consider predictors of treatment failure, particularly drug resistance, which is more common with genotype 3. Close monitoring for signs of failure and awareness of salvage therapy options are essential."

Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Fibrosis • Heart Failure • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Pain • Solid Organ Transplantation

Lung Transplant HCV, Pilot Study (clinicaltrials.gov) - P1 | N=26 | Active, not recruiting | Sponsor: University Health Network, Toronto | Trial completion date: Dec 2024 ➔ May 2026

Trial completion date • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Transplantation

Sustained Virological Response After Direct-Acting Antiviral Therapy in Hepatitis C Virus-Infected Individuals With and Without Decompensated Liver Cirrhosis: A One-Year Follow-Up Study. (PubMed, Cureus) - "In the National Viral Hepatitis Control Program (NVHCP), direct-acting antiviral (DAA) therapy (sofosbuvir and velpatasvir, without ribavirin) is used to achieve sustained virological response (SVR) in hepatitis C virus (HCV)-infected individuals. All CLD patients achieved SVR at 12 weeks after initiation of therapy (100%), which persisted at six months and one-year follow-up. Conclusion DAA therapy is highly effective, achieving a 100% SVR rate and sustained liver function improvement in HCV-infected patients with liver disease."

Journal • Fibrosis • Gastroenterology • Hepatitis C • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis

C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV (clinicaltrials.gov) - P3 | N=800 | Recruiting | Sponsor: Atea Pharmaceuticals, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Hepatitis C • Hepatology • Infectious Disease • Inflammation

Simplified HCV Treatment for Eligible Patients with Pan-Genotypic Regimens (APASL 2025) - "Pangenotypic DAAs, i.e. glecaprevir/pibrentasvir for 8 weeks or sofosbuvir/velpatasvir for 12 weeks, should be used to simplify the treatment. Assessment for other causes of liver disease is recommended for patients with elevated transaminase levels after achieving sustained virologic response. Patients with advanced liver fibrosis who achieve sustained virologic response should undergo surveillance for HCC every 6 months by means of imaging and serum tumor markers."

Clinical • Chronic Kidney Disease • Fibrosis • Gastroenterology • Hepatitis B • Hepatitis C • Hepatocellular Cancer • Hepatology • Human Immunodeficiency Virus • Immunology • Liver Cirrhosis • Liver Failure • Nephrology • Oncology • Renal Disease • Solid Organ Transplantation • Solid Tumor

Government-Led Early Screening, Prevention, and Treatment Program for Viral Hepatitis: Results and Insights (APASL 2025) - "54.55% (6/11) initiated treatment with sofosbuvir/velpatasvir... The government-led program significantly improved the diagnosis and treatment rates of HBV and HCV in the general population. This integrated model demonstrates a promising strategy for achieving viral hepatitis elimination targets and provides valuable insights for similar public health initiatives."

Hepatitis B • Hepatitis C • Hepatology • Infectious Disease • Inflammation

Current status of HCV Micro-elimination in a detoxification center in Chongqing, Southwestern China (APASL 2025) - "Furthermore, we established "E-Referral pathways" for HCV-RNA(+) patients, which include no-appointment consultations, remote consultations, reimbursement Sofosbuvir/Velpatasvir (SOF/VEL) agents, free medication referral from hospital to detoxification center, and face-to-face Q&A sessions during treatment... Education and "E-Referral pathways" can help to enhance the willingness of HCV screening and treatment among PWUDs. However, the lack of funding for testing and treatment remains a significant barrier for HCV micro-elimination in detoxification center. This issue highlights the pressing need for augmented financial assistance from both societal and governmental sectors to support this vulnerable population."

Fibrosis • Gastroenterology • Hepatitis C • Hepatology • Immunology • Liver Cancer • Liver Cirrhosis • Oncology • Solid Tumor

Latest Research Progress in Hepatitis C Therapy (APASL 2025) - "Research confirms that the combination of sofosbuvir and ledipasvir (e.g., Harvoni®) is sufficient to treat acute HCV infection within six weeks, with excellent tolerability and efficacy...In the trial, the combination of sofosbuvir and velpatasvir (Epclusa®), with or without ribavirin, administered for 12 or 24 weeks, successfully treated 83% to 94% of HCV patients... In summary, the field of Hepatitis C treatment is undergoing rapid advancements, particularly in the development and application of direct-acting antiviral agents (DAAs). These novel therapies not only achieve higher cure rates but also significantly shorten treatment duration and improve patients' quality of life. With ongoing research progress, future efforts are expected to yield additional innovative therapies and refined treatment strategies to further address the challenges posed by Hepatitis C."

Fibrosis • Hepatitis C • Hepatocellular Cancer • Hepatology • Infectious Disease • Inflammation • Liver Cirrhosis • Liver Failure • Oncology • Solid Tumor

Tumor Shrinkage Following Epclusa Treatment: Exploring Potential Role of Direct-Acting Antivirals in HCV-Related Hepatocellular Carcinoma (APASL 2025) - "This case reveals potential role of antiviral therapy in reducing HCC risk and improving patient outcomes. Future research should focus on understanding specific mechanisms by which DAAs influence HCC and evaluate their clinical effects in diverse patient populations to optimize treatment strategies for those with HCV-related HCC."

Fibrosis • Hepatitis C • Hepatocellular Cancer • Hepatology • Immunology • Liver Cirrhosis • Oncology • Solid Tumor • AFP

A multi-center, prospective, single-arm trial followed by an 12/48 week observational clinical trial to evaluate the safety and efficacy of SOF/VEL treatment and prophylactic use of TAF in patients with GT1-6 HCV/HBV coinfection (APASL 2025) - "In this study, we assessed the safety and efficacy of sofosbuvir/velpatasvir (SOF/VEL) in HBV/HCV coinfected patients from thirteen centers in China, and evaluated prophylactic use of tenofovir alafenamide (TAF) for HBV reactivation... SOF/VEL greatly reduces HCV RNA levels and improves liver function in patients with chronic HBV/HCV co-infection, with high safety. Patients with compensated cirrhosis also have significant improvement in indicators of cirrhosis after antiviral therapy. Additionally, prophylactic use of TAF in patients with chronic HBV/HCV coinfection prevents HBV reactivation to some extent."

Clinical • Fibrosis • Hepatitis B • Hepatitis C • Hepatology • Immunology • Inflammation • Liver Cirrhosis

Glecaprevir/Pibrentasvir in HIV/HCV-coinfected patients treated with bictegravir (APASL 2025) - "One of the most commonly used highly active antiretroviral therapy (HAART) is bictegravir/emtricitabine/tenofovir alafenamide (B/FTC/TAF). It has been proven that coadministration of B/FTC/TAF and sofosbuvir/velpatasvir (SOF/VEL) is unlikely to induce clinically significant interactions, however, coadministration of B/FTC/TAF with gelcaprevir/pibrentasvir (GLE/PIB) has not been studied...Of these, 38 were treated with GLE/PIB and 101 were treated with SOF/VEL ± ribavirin (RBV)... To our knowledge, this is one of the first studies to assess the real-life effectiveness and safety of GLE/PIB in HIV/HCV-positive patients treated with bictegravir. The study showed that real-life results of therapy with GLE/PIB or SOF/VEL did not differ significantly in HIV/HCV-coinfected patients treated with B/FTC/TAF. Both regimens allowed encouraging SVR12 rates and treatment safety, as well as tolerability, were also comparable between the study groups."

Clinical • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Liver Failure

Resident physician-leading HCV micro-elimination strategy in a tertiary hospital: identification of diagnosed but untreated patients and linkage to care (APASL 2025) - "When patients came back, resident physician will provide a "fast-track referral pathways" throughout screening and treatment—no appointment required, free infectious disease(ID) department specialist clinic visit, immediate HCV RNA testing, and reimbursed Sofosbuvir/Velpatasvir (SOF/VEL) treatment... Resident physician took an important role through this in-hospital HCV micro-elimination strategy. We helped to identify 47.3% DBU patients and found that many patients were from non-ID departments. Unfortunately, more than 40% of the patients had already experienced advanced liver disease progression or death, which demonstrate the importance of establish the stander of process for HCV micro-elimination in non-ID department."

Clinical • Fibrosis • Hepatitis C • Hepatocellular Cancer • Hepatology • Immunology • Oncology • Solid Tumor